BR112018002172A2 - promotores para intensificar a expressão em poxvírus - Google Patents

promotores para intensificar a expressão em poxvírus

Info

Publication number
BR112018002172A2
BR112018002172A2 BR112018002172A BR112018002172A BR112018002172A2 BR 112018002172 A2 BR112018002172 A2 BR 112018002172A2 BR 112018002172 A BR112018002172 A BR 112018002172A BR 112018002172 A BR112018002172 A BR 112018002172A BR 112018002172 A2 BR112018002172 A2 BR 112018002172A2
Authority
BR
Brazil
Prior art keywords
enhance
promoters
expression
poxvirus expression
poxvirus
Prior art date
Application number
BR112018002172A
Other languages
English (en)
Other versions
BR112018002172A8 (pt
Inventor
Delcayre Alain
Rountree Ryan
Li Zengji
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of BR112018002172A2 publication Critical patent/BR112018002172A2/pt
Publication of BR112018002172A8 publication Critical patent/BR112018002172A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção diz respeito a um ou mais promotores e/ou cassetes de expressão que podem ser utilizados para intensificar a expressão de um gene heterólogo, tal como brachyury. em particular, o um ou mais promotores e/ou cassetes de expressão intensificam a expressão de genes heterólogos como parte de um vetor viral, tal como um poxvírus.
BR112018002172A 2015-07-31 2016-07-28 Promotores para intensificar a expressão em poxvírus BR112018002172A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199681P 2015-07-31 2015-07-31
PCT/IB2016/001183 WO2017021776A1 (en) 2015-07-31 2016-07-28 Promoters for enhancing expression in poxviruses

Publications (2)

Publication Number Publication Date
BR112018002172A2 true BR112018002172A2 (pt) 2018-09-18
BR112018002172A8 BR112018002172A8 (pt) 2024-02-15

Family

ID=57068152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002172A BR112018002172A8 (pt) 2015-07-31 2016-07-28 Promotores para intensificar a expressão em poxvírus

Country Status (17)

Country Link
US (1) US11753652B2 (pt)
EP (1) EP3329016B1 (pt)
JP (1) JP6851364B2 (pt)
KR (1) KR102565284B1 (pt)
CN (1) CN107922981B (pt)
AU (1) AU2016303378B2 (pt)
BR (1) BR112018002172A8 (pt)
CA (1) CA2990549A1 (pt)
DK (1) DK3329016T3 (pt)
ES (1) ES2901468T3 (pt)
HK (1) HK1254405A1 (pt)
IL (1) IL256869B (pt)
MX (1) MX2018001055A (pt)
RU (1) RU2753884C2 (pt)
SG (1) SG10202000447YA (pt)
WO (1) WO2017021776A1 (pt)
ZA (1) ZA201800104B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019038388A1 (en) 2017-08-24 2019-02-28 Bavarian Nordic A/S POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
JP2022512595A (ja) 2018-10-05 2022-02-07 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
EP3883599A1 (en) 2018-11-20 2021-09-29 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
EP4061406A1 (en) 2019-11-20 2022-09-28 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CA3240596A1 (en) 2021-12-23 2023-06-29 Cigdem ATAY LANGBEIN Therapy for modulating immune response with recombinant mva encoding il-12

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
EP0538496B1 (en) * 1991-08-26 2003-10-29 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
RU2180352C2 (ru) 1999-11-24 2002-03-10 Государственный научный центр вирусологии и биотехнологии "Вектор" ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
EP1673458A4 (en) * 2003-10-15 2007-12-12 Virax Dev Pty Ltd FOR RETROVIRUS (e.g., HIV) AND CYTOKIN-CODING POXVIRUS VECTOR
DK2918598T3 (en) * 2007-02-28 2019-04-29 The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services Brachyury polypeptides and methods of use
CN101775410B (zh) 2009-01-09 2011-11-16 中国人民解放军军事医学科学院军事兽医研究所 一种鸡痘病毒载体穿梭质粒及其应用
CA2759013C (en) 2009-04-17 2021-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy compositions against cancer and methods
CN102321637A (zh) 2011-09-09 2012-01-18 中国人民解放军军事医学科学院军事兽医研究所 中国鸡痘病毒282e4弱毒株全基因组序列及其应用
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer

Also Published As

Publication number Publication date
JP6851364B2 (ja) 2021-03-31
US20180216134A1 (en) 2018-08-02
BR112018002172A8 (pt) 2024-02-15
AU2016303378A1 (en) 2018-01-25
ES2901468T3 (es) 2022-03-22
DK3329016T3 (da) 2022-01-10
KR102565284B1 (ko) 2023-08-08
RU2018106643A (ru) 2019-08-28
KR20180033498A (ko) 2018-04-03
CN107922981B (zh) 2022-02-25
CN107922981A (zh) 2018-04-17
RU2018106643A3 (pt) 2020-01-30
MX2018001055A (es) 2018-05-17
EP3329016A1 (en) 2018-06-06
JP2018521651A (ja) 2018-08-09
EP3329016B1 (en) 2021-10-20
HK1254405A1 (zh) 2019-07-19
CA2990549A1 (en) 2017-02-09
SG10202000447YA (en) 2020-03-30
AU2016303378B2 (en) 2021-12-23
RU2753884C2 (ru) 2021-08-24
ZA201800104B (en) 2022-04-28
WO2017021776A1 (en) 2017-02-09
IL256869A (en) 2018-03-29
IL256869B (en) 2022-07-01
US11753652B2 (en) 2023-09-12

Similar Documents

Publication Publication Date Title
BR112018002172A2 (pt) promotores para intensificar a expressão em poxvírus
MX2021005226A (es) Regulacion de expresion genica mediada por nucleasa.
PH12018501159A1 (en) Composition and methods for immunooncology
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
EA201690403A1 (ru) Композиции и способы для модулирования рнк
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
UY35385A (es) ?métodos y composiciones para el control de malezas?.
CR20140538A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modificación de la transcripción dirigida por arn
MY195389A (en) Therapeutic HPV18 Vaccines
MY181175A (en) Therapeutic hpv16 vaccines
MX2017016400A (es) Vectores para uso en un sistema de coexpresion inducible.
DOP2022000085A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112019004594A2 (pt) terapia genética para pacientes com anemia de fanconi
MY165601A (en) Heat-absorbent and radiant steel sheet, and heat-absorbent and radiant member
MX2017016623A (es) Variantes de quimosina con propiedades mejoradas.
EP3414650A4 (en) SOCIAL KEYBOARD
MX2018002366A (es) Variantes de quimosina con propiedades mejoradas.
MX2022001801A (es) Secuencias recombinantes de cromosoma b de maiz y sus usos.
MX2021006326A (es) Inhibidores de pcna.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
EP3373938A4 (en) NOVEL RNA-BASED VECTOR SYSTEM FOR TEMPORARY AND STABLE GENE EXPRESSION
MY187959A (en) Reactor
BR112017024855A2 (pt) métodos de produção de aldc
MX2017002768A (es) Agentes antivirales y usos de los mismos.
EP3305904A4 (en) PROMOTER DERIVED FROM POXVIRUS, AND VECTOR COMPRISING SAME

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2016, OBSERVADAS AS CONDICOES LEGAIS